EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Efficacy of different administration methods of vonoprazan for gastroesophageal reflux disease: a retrospective cohort study

Qianqian Wu, Di Li, Lu Li, Shuang Chen, Wenting Xu, Jiale Zhang, Huili Wu, Feifei Chu, Kunkun Li, Lihong Wang

Diseases of the Esophagus · 2025-09-01 · 38 (5)

DOI: 10.1093/dote/doaf092 ↗
AbstractBibliografische Angaben

Abstract

Summary Vonoprazan, a potassium competitive acid blocker (P-CAB), shows promise for gastroesophageal reflux disease (GERD). On-demand therapy may reduce costs and drug exposure. This study aimed to compare the efficacy of on-demand versus continuous vonoprazan treatment in the initial management of mild GERD. This observational cohort study enrolled patients with non-erosive reflux disease (NERD) and mild reflux esophagitis (LA grade A/B). Patients were allocated to either on-demand or continuous vonoprazan (20 mg/day) treatment for 4 weeks. Primary outcomes were changes in Gastroesophageal Reflux Disease Questionnaire (GerdQ) and Gastroesophageal Reflux Disease Health-Related Quality of Life (GERD-HRQL) scores. Secondary outcomes included treatment satisfaction, complete mucosal healing rate, and 24-week relapse rate. The GerdQ score and GERD-HRQL score of the on-demand treatment group decreased significantly after initial treatment compared with the previous one, with statistical significance (P < 0.001). Moreover, there were no significant differences in GerdQ and GERD-HRQL scores between the two groups after the treatment (P = 0.363, P = 0.037; the significance level was P < 0.025). Satisfaction (75.9% vs. 74.3%), complete mucosal healing rates (61.8% vs. 38.8%), and relapse rates (10.2% vs. 8.9%) were comparable in the on-demand and continuous treatment groups. Age (OR = 1.08, 95% CI: 1.05–1.11, P < 0.001) and alcohol consumption (OR = 4.31, 95% CI: 1.06–17.41, P = 0.04) were influential factors for symptom burden improvement, and treatment allocation (P = 0.069) had no significant effect on symptom burden improvement. Age (OR = 0.94, 95% CI: 0.91–0.96, P < 0.001) and pre-treatment Los Angeles grade B (OR = 3.28, 95% CI: 1.46–7.34, P = 0.004) were predictors of improved quality of life. This study found on-demand vonoprazan demonstrates comparable efficacy to continuous therapy for mild GERD, offering a cost-effective strategy with minimized drug accumulation risks.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →